OBJECTIVE：To explore the role of clinical evidence-based pharmacy in anticoagulant treatment strategies during continuous renal replacement therapy （CRRT）. METHODS：Taking a thrombocytopenia patient of anticoagulant treatment during CRRT for instance， clinical pharmacists analyzed the evidence of taken argatroban anticoagulant therapy during CRRT for high risk blooding and thrombocytopenia patients based on evidence-based pharmacy combined with clinical data， monitored the efficacy and safety and evaluated the treatment process. RESULTS：Totally five literature about anticoagulant treatment strategies during CRRT for high risk blooding and thrombocytopenia patients were obtained，including one systematic review， one RCT and three cohort studies. Based on the above evidences， good results were achieved in the clinical practice of this patient， no thrombotic or hemorrhagic complications occurred in this patient， platelet count and coagulation indicators of patients also improved. CONCLUSIONS：Evidence-based pharmacy plays an important role in anticoagulant treatment strategies during CRRT.